|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kondo T, Ezzat S and Asa SL: Pathogenetic
mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer.
6:292–306. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sipos JA and Mazzaferri EL: Thyroid cancer
epidemiology and prognostic variables. Clin Oncol (R Coll Radiol).
22:395–404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loh KC, Greenspan FS, Gee L, Miller TR and
Yeo PP: Pathological tumor-node-metastasis (pTNM) staging for
papillary and follicular thyroid carcinomas: A retrospective
analysis of 700 patients. J Clin Endocrinol Metab. 82:3553–3562.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chou CK, Yang KD, Chou FF, Huang CC, Lan
YW, Lee YF, Kang HY and Liu RT: Prognostic implications of miR-146b
expression and its functional role in papillary thyroid carcinoma.
J Clin Endocrinol Metab. 98:E196–E205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lang BH, Wong KP, Wan KY and Lo CY:
Significance of metastatic lymph node ratio on stimulated
thyroglobulin levels in papillary thyroid carcinoma after
prophylactic unilateral central neck dissection. Ann Surg Oncol.
19:1257–1263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiang J, Wu Y, Li DS, Wang ZY, Shen Q, Sun
TQ, Guan Q and Wang YJ: miR-584 suppresses invasion and cell
migration of thyroid carcinoma by regulating the target oncogene
ROCK1. Oncol Res Treat. 38:436–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orang A Valinezhad, Safaralizadeh R and
Kazemzadeh-Bavili M: Mechanisms of miRNA-mediated gene regulation
from common downregulation to mRNA-specific upregulation. Int J
Genomics. 2014:9706072014.PubMed/NCBI
|
|
10
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shukla GC, Singh J and Barik S: MicroRNAs:
processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
13
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Z, Huang X, Xu J, Su Q, Zhao J and Ma
J: miR-449 overexpression inhibits papillary thyroid carcinoma cell
growth by targeting RET kinase-β-catenin signaling pathway. Int J
Oncol. 49:1629–1637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang G, Fu Y, Liu G, Ye Y and Zhang X:
miR-218 inhibits proliferation, migration, and EMT of gastric
cancer cells by targeting WASF3. Oncol Res. 25:355–364. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan Y, Peng Y, Ou Y and Jiang Y:
MicroRNA-610 is downregulated in glioma cells, and inhibits
proliferation and motility by directly targeting MDM2. Mol Med Rep.
14:2657–2664. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Zhao X, Shi J, Pan Y, Chen Q, Leng
P and Wang Y: miR-451 suppresses bladder cancer cell migration and
invasion via directly targeting c-Myc. Oncol Rep. 36:2049–2058.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Li H, Wang Y, Wang L, Yan X, Zhang
D, Ma X, Du Y, Liu X and Yang Y: MicroRNA-552 enhances metastatic
capacity of colorectal cancer cells by targeting a disintegrin and
metalloprotease 28. Oncotarget. 7:70194–70210. 2016.PubMed/NCBI
|
|
21
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y
and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular
carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer
Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu K and Liang M: Upregulated microRNA-224
promotes ovarian cancer cell proliferation by targeting KLLN. In
Vitro Cell Dev Biol Anim. 53:149–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia P and Xu XY: PI3K/Akt/mTOR signaling
pathway in cancer stem cells: From basic research to clinical
application. Am J Cancer Res. 5:1602–1609. 2015.PubMed/NCBI
|
|
26
|
Petrulea MS, Plantinga TS, Smit JW,
Georgescu CE and Netea-Maier RT: PI3K/Akt/mTOR: A promising
therapeutic target for non-medullary thyroid carcinoma. Cancer
Treat Rev. 41:707–713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Z, Li X, Cai X, Huang C and Zheng M:
miR-497 inhibits epithelial mesenchymal transition in breast
carcinoma by targeting Slug. Tumour Biol. 37:7939–7950. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han L, Liu B, Jiang L, Liu J and Han S:
MicroRNA-497 downregulation contributes to cell proliferation,
migration, and invasion of estrogen receptor alpha negative breast
cancer by targeting estrogen-related receptor alpha. Tumour Biol.
37:13205–13214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Zhou Y, Shi Z, Hu Y, Meng T, Zhang
X, Zhang S and Zhang J: microRNA-497 modulates breast cancer cell
proliferation, invasion, and survival by targeting SMAD7. DNA Cell
Biol. 35:521–529. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang L, Jiang CF, Li DM, Ge X, Shi ZM, Li
CY, Liu X, Yin Y, Zhen L, Liu LZ and Jiang BH: MicroRNA-497
inhibits tumor growth and increases chemosensitivity to
5-fluorouracil treatment by targeting KSR1. Oncotarget.
7:2660–2671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo M, Shen D, Zhou X, Chen X and Wang W:
MicroRNA-497 is a potential prognostic marker in human cervical
cancer and functions as a tumor suppressor by targeting the
insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang L, Yu Z, Xian Y and Lin X:
microRNA-497 inhibits cell proliferation and induces apoptosis by
targeting YAP1 in human hepatocellular carcinoma. FEBS Open Bio.
6:155–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao X, Zhao Z, Xu W, Hou J and Du X:
Down-regulation of miR-497 is associated with poor prognosis in
renal cancer. Int J Clin Exp Pathol. 8:758–764. 2015.PubMed/NCBI
|
|
35
|
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA,
Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497
promotes tumor growth and angiogenesis by targeting HDGF in
non-small cell lung cancer. Biochem Biophys Res Commun.
435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Li B, Li L and Wang T:
MicroRNA-497 suppresses proliferation and induces apoptosis in
prostate cancer cells. Asian Pac J Cancer Prev. 14:3499–3502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu J, Wang T, Cao Z, Huang H, Li J, Liu W,
Liu S, You L, Zhou L, Zhang T and Zhao Y: MiR-497 downregulation
contributes to the malignancy of pancreatic cancer and associates
with a poor prognosis. Oncotarget. 5:6983–6993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin Z, Zhao J, Wang X, Zhu X and Gong L:
Overexpression of microRNA-497 suppresses cell proliferation and
induces apoptosis through targeting paired box 2 in human ovarian
cancer. Oncol Rep. 36:2101–2107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Y, Zhang Z, Li Z, Gong D, Zhan B,
Man X and Kong C: MicroRNA-497 inhibits the proliferation,
migration and invasion of human bladder transitional cell carcinoma
cells by targeting E2F3. Oncol Rep. 36:1293–1300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu Q, Wang H, Singh A and Shou F:
Expression and function of microRNA-497 in human osteosarcoma. Mol
Med Rep. 14:439–445. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Luo Q, Li X, Gao Y, Long Y, Chen L, Huang
Y and Fang L: MiRNA-497 regulates cell growth and invasion by
targeting cyclin E1 in breast cancer. Cancer Cell Int. 13:952013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qiu Y, Yu H, Shi X, Xu K, Tang Q, Liang B,
Hu S, Bao Y, Xu J, Cai J, et al: microRNA-497 inhibits invasion and
metastasis of colorectal cancer cells by targeting vascular
endothelial growth factor-A. Cell Prolif. 49:69–78. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han J, Huo M, Mu M, Liu J and Zhang J:
miR-497 suppresses proliferation of human cervical carcinoma HeLa
cells by targeting cyclin E1. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
30:597–600. 2014.(In Chinese). PubMed/NCBI
|
|
46
|
Ding WZ, Ni QF, Lu YT, Kong LL, Yu JJ, Tan
LW and Kong LB: MicroRNA-497 regulates cell proliferation in
hepatocellular carcinoma. Oncol Lett. 11:1081–1088. 2016.PubMed/NCBI
|
|
47
|
Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y,
Li PY, Wang M, Lin JS and He XX: MiR-497 suppresses angiogenesis
and metastasis of hepatocellular carcinoma by inhibiting VEGFA and
AEG-1. Oncotarget. 6:29527–29542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Han Z, Zhang Y, Yang Q, Liu B, Wu J, Zhang
Y, Yang C and Jiang Y: miR-497 and miR-34a retard lung cancer
growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget.
6:13149–13163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang C, Ma R, Yue J, Li N, Li Z and Qi D:
MiR-497 Suppresses YAP1 and inhibits tumor growth in non-small cell
lung cancer. Cell Physiol Biochem. 37:342–352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gu A, Lu J, Wang W, Shi C, Han B and Yao
M: Role of miR-497 in VEGF-A-mediated cancer cell growth and
invasion in non-small cell lung cancer. Int J Biochem Cell Biol.
70:118–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wu D, Niu X, Pan H, Zhang Z, Zhou Y, Qu P
and Zhou J: MicroRNA-497 targets hepatoma-derived growth factor and
suppresses human prostate cancer cell motility. Mol Med Rep.
13:2287–2292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kong XJ, Duan LJ, Qian XQ, Xu D, Liu HL,
Zhu YJ and Qi J: Tumor-suppressive microRNA-497 targets IKKβ to
regulate NF-κB signaling pathway in human prostate cancer cells. Am
J Cancer Res. 5:1795–1804. 2015.PubMed/NCBI
|
|
53
|
Xu S, Fu GB, Tao Z, OuYang J, Kong F,
Jiang BH, Wan X and Chen K: MiR-497 decreases cisplatin resistance
in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang W, Ren F, Wu Q, Jiang D, Li H, Peng
Z, Wang J and Shi H: MicroRNA-497 inhibition of ovarian cancer cell
migration and invasion through targeting of SMAD specific E3
ubiquitin protein ligase 1. Biochem Biophys Res Commun.
449:432–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ge L, Zheng B, Li M, Niu L and Li Z:
MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in
vivo. Oncol Lett. 11:2207–2212. 2016.PubMed/NCBI
|
|
56
|
Ruan WD, Wang P, Feng S, Xue Y and Zhang
B: MicroRNA-497 inhibits cell proliferation, migration, and
invasion by targeting AMOT in human osteosarcoma cells. Onco
Targets Ther. 9:303–313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Agarwal E, Brattain MG and Chowdhury S:
Cell survival and metastasis regulation by Akt signaling in
colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kang B, Hao C, Wang H, Zhang J, Xing R,
Shao J, Li W, Xu N, Lu Y and Liu S: Evaluation of
hepatic-metastasis risk of colorectal cancer upon the protein
signature of PI3K/AKT pathway. J Proteome Res. 7:3507–3515. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ma Y, She XG, Ming YZ, Wan QQ and Ye QF:
MicroRNA144 suppresses tumorigenesis of hepatocellular carcinoma by
targeting AKT3. Mol Med Rep. 11:1378–1383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lin HP, Lin CY, Huo C, Jan YJ, Tseng JC,
Jiang SS, Kuo YY, Chen SC, Wang CT, Chan TM, et al: AKT3 promotes
prostate cancer proliferation cells through regulation of Akt,
B-Raf, and TSC1/TSC2. Oncotarget. 6:27097–27112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cheng JQ, Ruggeri B, Klein WM, Sonoda G,
Altomare DA, Watson DK and Testa JR: Amplification of AKT2 in human
pancreatic cells and inhibition of AKT2 expression and
tumorigenicity by antisense RNA. Proc Natl Acad Sci USA.
93:3636–3641. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Altomare DA, Tanno S, De Rienzo A,
Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP and Testa JR:
Frequent activation of AKT2 kinase in human pancreatic carcinomas.
J Cell Biochem. 87:470–476. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mure H, Matsuzaki K, Kitazato KT,
Mizobuchi Y, Kuwayama K, Kageji T and Nagahiro S: Akt2 and Akt3
play a pivotal role in malignant gliomas. Neuro Oncol. 12:221–232.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chin YR, Yoshida T, Marusyk A, Beck AH,
Polyak K and Toker A: Targeting Akt3 signaling in triple-negative
breast cancer. Cancer Res. 74:964–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li R, Liu J, Li Q, Chen G and Yu X:
miR-29a suppresses growth and metastasis in papillary thyroid
carcinoma by targeting AKT3. Tumour Biol. 37:3987–3996. 2016.
View Article : Google Scholar : PubMed/NCBI
|
